Title: PHARMAMAR-COMPANY REPORT
Price: $1,760.00
Published: Oct 17, 2007
Source: LIFE SCIENCE ANALYTICS
Author: HARINATHA, G.
Company: PHARMAMAR SA
Geographic Region: EUROPE, SPAIN, WESTERN EUROPE REGION
Brief Excerpt: ...PharmaMar is a biopharmaceutical company committed to advancing the treatment of cancer through the discovery and development of new marine-derived medi cines. It was founded in #### with the vision of exploiting the great potential of t he oceans as a source of novel medi cines for improved cancer treatment. The company is a subsidiary of Zeltia Group. PharmaMar supports the protection, conservation and sustainable use of the precious res ources from the sea. Its approach to drug discovery not only contributes to potential novel therapeutics from just a few grams of marine sample but also to the better knowledge of the local marine ecosystems and their conservation. The company has created a collaborative network to speed up research on its collection of potentially acti ve agents. This network includes centers of marine biology and chemistry, which have facilitated access to marine samples (micro- as well as macro- organisms), and world-class basic science and clinical...
Length: 44 Pages
Format: Adobe Acrobat
16 noviembre 2007
NeuroPharma , Nuevo informe .....lo malo es que cuesta 520 $$$ .
Title: NEUROPHARMA, S.A.-COMPANY REPORT
Price: $520.00
Published: Nov 07, 2007
Source: LIFE SCIENCE ANALYTICS
Author: HARINATHA, G.
Company: NEUROPHARMA SA
Geographic Region: EUROPE, SPAIN, WESTERN EUROPE REGION
Brief Excerpt: ...Avda. de la Industria, ##, Pa rque Tecnologico de Madrid, Tres Cantos ##### Madrid, Spain email: neuropharma@neuropharma.es Website: http://www.neuropharma.es phone: ##-##-###-##-## ...
Length: 13 Pages
Format: Adobe Acrobat
Price: $520.00
Published: Nov 07, 2007
Source: LIFE SCIENCE ANALYTICS
Author: HARINATHA, G.
Company: NEUROPHARMA SA
Geographic Region: EUROPE, SPAIN, WESTERN EUROPE REGION
Brief Excerpt: ...Avda. de la Industria, ##, Pa rque Tecnologico de Madrid, Tres Cantos ##### Madrid, Spain email: neuropharma@neuropharma.es Website: http://www.neuropharma.es phone: ##-##-###-##-## ...
Length: 13 Pages
Format: Adobe Acrobat
Renta 4 incrementa participacion en Zeltia .
Claves de la semana entrante y cambios en carteras . 16/11/07 18:30
En la cartera española de largo plazo, reducimos un 2% en BBVA (hasta 11%) por los motivos anteriormente expuestos, e incrementamos 1 pp en Santander (hasta 13%) y en Zeltia (+4%) aprovechando los últimos recortes.
En las carteras por perfiles, no realizamos cambios en la conservadora. En la moderada, sale BBVA y en su lugar entra Carrefour, mientras que en la tolerante damos salida a Europac (aunque en el medio plazo la seguimos considerando como una atractiva oportunidad de inversión) para incluir a Zeltia, donde vemos oportunidad de compra tras los últimos recortes.
En la cartera española de largo plazo, reducimos un 2% en BBVA (hasta 11%) por los motivos anteriormente expuestos, e incrementamos 1 pp en Santander (hasta 13%) y en Zeltia (+4%) aprovechando los últimos recortes.
En las carteras por perfiles, no realizamos cambios en la conservadora. En la moderada, sale BBVA y en su lugar entra Carrefour, mientras que en la tolerante damos salida a Europac (aunque en el medio plazo la seguimos considerando como una atractiva oportunidad de inversión) para incluir a Zeltia, donde vemos oportunidad de compra tras los últimos recortes.
Yondelis ¿ A la venta ya en 6 Paises Europeos ? .
Pregunta: ¿Ya tienen fecha para iniciar la comercialización de Yondelis en Alemania y Reino Unido?
Respuesta: Este mismo mes se empezará a vender en Alemania y Reino Unido. Inmediatamente después, es decir, en un plazo de dos a tres semanas, se iniciará la venta en Dinamarca, Suecia, Finlandia y Noruega, países con los cuales tampoco es necesario negociar el precio de venta.
Respuesta: Este mismo mes se empezará a vender en Alemania y Reino Unido. Inmediatamente después, es decir, en un plazo de dos a tres semanas, se iniciará la venta en Dinamarca, Suecia, Finlandia y Noruega, países con los cuales tampoco es necesario negociar el precio de venta.
Ram Bhavnani donara todos los ingresos que genere la venta de su libro : " secretos para ganar en bolsa " a la asociacion contra el Cancer de Tenerife
Madrid. Ram Bhavnani llegó a España en 1965 para ocuparse en Tenerife de la tienda textil de su suegro. En 1983 se estrenó en bolsa con 120.000 euros y, tras gestionar con maestría las inversiones, se ha convertido en el segundo mayor accionista de Bankinter. Con casi el 15% del capital y a punto de estrenar un puesto en la comisión ejecutiva del consejo, sortea cortés las inevitables preguntas sobre operaciones corporativas en Bankinter porque "soy consejero" Pero admite que "como inversor, todo tiene un precio" en un encuentro previo a la presentación de su libro Los secretos para ganar dinero en la Bolsa, cuyos ingresos se donarán a la Asociación contra el Cáncer de Tenerife.
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME.
Br J Cancer. 2007 Nov 13; [Epub ahead of print]
1Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis((R))) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Phase II trial of trabectedin in patients with advanced recurrent ovarian cancer. Trabectedin (0.58 mg m(-2)) was administered via a central line, after premedication with dexamethasone, to 147 patients as a 3-h infusion weekly for 3 weeks followed by 1-week rest. Major eligibility criteria included measurable relapsed advanced ovarian cancer and not more than two prior platinum-containing regimens. Patients were stratified according to the treatment-free interval (TFI) between having either platinum-sensitive (>/=6 months TFI) or platinum-resistant disease (<6 months TFI)/platinum-refractory disease (progression during first line therapy). In the platinum-sensitive cohort, 62 evaluable patients with measurable disease had an overall response rate (ORR) of 29.0% (95% CI: 18.2-41.9%) and median progression-free survival (PFS) was 5.1 months (95% CI: 2.8-6.2). Four patients with measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) criteria had no follow-up scans at the end of treatment. In the platinum-resistant/refractory cohort, 79 patients were evaluable with an ORR of 6.3% (95% CI: 2.1-14.2%). Median PFS was 2.0 months (95% CI: 1.7-3.5 months). Two patients with measurable disease per RECIST criteria had no follow-up scans at the end of treatment. The most frequent (>/=2% of patients) drug-related treatment-emergent grade 3/4 adverse events were reversible liver alanine transferase elevation (10%), neutropaenia (8%), nausea, vomiting, and fatigue (5% each). Trabectedin is an active treatment, with documented responses in patients with platinum sensitive advanced relapsed ovarian cancer, and has a manageable toxicity profile.British Journal of Cancer advance online publication, 13 November 2007; doi:10.1038/sj.bjc.6604088 www.bjcancer.com.
Date of Electronic Publication: 2007 Nov 13
Publication Status: aheadofprint
PMID: 18000504 [PubMed - as supplied by publisher]
Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME.
Br J Cancer. 2007 Nov 13; [Epub ahead of print]
1Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis((R))) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Phase II trial of trabectedin in patients with advanced recurrent ovarian cancer. Trabectedin (0.58 mg m(-2)) was administered via a central line, after premedication with dexamethasone, to 147 patients as a 3-h infusion weekly for 3 weeks followed by 1-week rest. Major eligibility criteria included measurable relapsed advanced ovarian cancer and not more than two prior platinum-containing regimens. Patients were stratified according to the treatment-free interval (TFI) between having either platinum-sensitive (>/=6 months TFI) or platinum-resistant disease (<6 months TFI)/platinum-refractory disease (progression during first line therapy). In the platinum-sensitive cohort, 62 evaluable patients with measurable disease had an overall response rate (ORR) of 29.0% (95% CI: 18.2-41.9%) and median progression-free survival (PFS) was 5.1 months (95% CI: 2.8-6.2). Four patients with measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) criteria had no follow-up scans at the end of treatment. In the platinum-resistant/refractory cohort, 79 patients were evaluable with an ORR of 6.3% (95% CI: 2.1-14.2%). Median PFS was 2.0 months (95% CI: 1.7-3.5 months). Two patients with measurable disease per RECIST criteria had no follow-up scans at the end of treatment. The most frequent (>/=2% of patients) drug-related treatment-emergent grade 3/4 adverse events were reversible liver alanine transferase elevation (10%), neutropaenia (8%), nausea, vomiting, and fatigue (5% each). Trabectedin is an active treatment, with documented responses in patients with platinum sensitive advanced relapsed ovarian cancer, and has a manageable toxicity profile.British Journal of Cancer advance online publication, 13 November 2007; doi:10.1038/sj.bjc.6604088 www.bjcancer.com.
Date of Electronic Publication: 2007 Nov 13
Publication Status: aheadofprint
PMID: 18000504 [PubMed - as supplied by publisher]
Suscribirse a:
Entradas (Atom)